• Users Online: 1053
  • Print this page
  • Email this page

    Article Cited by others

ORIGINAL ARTICLE

Phase 2 clinical trial of VAL-083 as first-line treatment in newly-diagnosed MGMT-unmethylated glioblastoma multiforme (GBM): Halfway report

Guo Chengcheng, Yang Qunying, Li Jiawei, Wu Shaoxiong, Deng Meiling, Du Xiaojing, Sai Ke, Jiang Xiaobing, Chen Zhenghe, Zhang Ji, Lin Fuhua, Wang Jian, Chen Yinsheng, Ke Chao, Zhang Xiangheng, Ju Xue, Mou Yonggao, Bacha Jeffrey, Steino Anne, Kanekal Sarath, Kwan Claire, Johnson Gregory, Schwartz Richard, Langlands John, Brown Dennis, Chen Zhong-ping

Year : 2019| Volume: 2| Issue : 4 | Page no: 167-173

   This article has been cited by
 
1 DNA Repair Mechanisms and Therapeutic Targets in Glioma
Kevin B. Elmore,Lauren R. Schaff
Current Oncology Reports. 2021; 23(8)
[Pubmed]  [Google Scholar] [DOI]
2 Dianhydrogalactitol Overcomes Multiple Temozolomide Resistance Mechanisms in Glioblastoma
Miguel Jiménez-Alcázar,Álvaro Curiel-García,Paula Nogales,Javier Perales-Patón,Alberto J. Schuhmacher,Marcos Galán-Ganga,Lucía Zhu,Scott W. Lowe,Fátima Al-Shahrour,Massimo Squatrito
Molecular Cancer Therapeutics. 2021; 20(6): 1029
[Pubmed]  [Google Scholar] [DOI]

 

Read this article